Grace Therapeutics, Inc.
GRCEHealthcare|Biotechnology|US
$1.85
+0.07 (+3.93%)
DCF Value
$0.70
Tangible Book / Share
$0.72
Cash / Share
$0.80
Financials
Financial Snapshot
Market Cap
$30.1M
Enterprise Value
$16.4M
Revenue (TTM)
$0.00
Net Income (TTM)
-$21.5M
Cash & Investments
$13.8M
Net Cash
$13.8M
Free Cash Flow (TTM)
-$10.3M
Operating CF (TTM)
-$10.3M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$13.8M
Quarterly Burn
$2.6M
Monthly Burn
$858.4K
Est. Runway
~5.3 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $9.8M | $6.4M | $25.8M | $20.1M | $76.3M | $43.7M | $27.9M | $23.0M | $22.1M | $17.0M | $13.8M | |
| Operating Cash Flow | -$6.9M | -$9.7M | -$24.8M | -$32.4M | -$18.0M | -$17.2M | -$15.9M | -$12.3M | -$14.9M | -$8.9M | -$10.3M | |
| Free Cash Flow | -$9.5M | -$10.0M | -$25.3M | -$32.9M | -$18.1M | -$17.2M | -$15.9M | -$12.4M | -$14.9M | -$8.9M | -$10.3M | |
| Capital Expenditure | -$2.6M | -$352.3K | -$534.0K | -$450.9K | -$86.7K | $0.00 | -$17.0K | -$22.0K | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $7.0M | $8.8M | $45.7M | $18.6M | $74.7M | $0.00 | $304.0K | $7.4M | $14.0M | $3.7M | $4.0M |
R&D Spending
R&D (TTM)
$2.5M
R&D Intensity
—
R&D Growth vs Prior
+5.7%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $309.3K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $7.2M | $12.1M | $29.4M | $31.9M | $6.6M | $6.9M | $13.5M | $6.4M | $13.5M | $2.4M | $2.5M | |
| R&D % of Revenue | — | — | — | — | 2129.1% | — | — | — | — | — | — | |
| SG&A | $768.7K | $3.1M | $4.3M | $16.9M | $10.5M | $12.2M | $11.1M | $9.0M | $10.2M | $8.7M | $7.5M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $309.3K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $2.6M | $2.7M | $3.1M | $0.00 | $119.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.0K | |
| Gross Profit | -$2.6M | -$2.7M | -$3.1M | $0.00 | $189.4K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2.0K | |
| R&D | $7.2M | $12.1M | $29.4M | $31.9M | $6.6M | $6.9M | $13.5M | $6.4M | $13.5M | $2.4M | $2.5M | |
| SG&A | $768.7K | $3.1M | $4.3M | $16.9M | $10.5M | $12.2M | $11.1M | $9.0M | $10.2M | $8.7M | $7.5M | |
| Operating Income | -$10.5M | -$15.3M | -$34.4M | -$48.8M | -$25.9M | -$19.5M | -$70.5M | -$17.4M | -$23.8M | -$11.1M | -$25.7M | |
| Interest Expense | $54.4K | $371.6K | $1.1M | $414.2K | $331.6K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$10.7M | -$16.7M | -$39.4M | -$51.0M | -$31.1M | -$13.1M | -$70.3M | -$19.9M | -$18.2M | -$9.5M | -$23.2M | |
| Net Income | -$10.6M | -$16.7M | -$39.4M | -$51.0M | -$31.1M | -$12.3M | -$57.4M | -$17.4M | -$13.6M | -$7.8M | -$21.5M | |
| EPS (Diluted) | -45.67 | -59.30 | -46.58 | -28.78 | -12.59 | -2.02 | -7.72 | -1.83 | -1.13 | -0.47 | -1.26 | |
| EBITDA | -$8.0M | -$14.3M | -$36.8M | -$47.4M | -$15.7M | -$19.2M | -$24.6M | -$15.4M | -$23.7M | -$11.1M | -$25.7M | |
| Shares Out. (M) | 0.23 | 0.36 | 1.13 | 1.76 | 2.47 | 6.14 | 7.44 | 9.53 | 12.09 | 16.51 | 17.27 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $0.00 | $6.4M | $16.9M | $20.1M | $64.0M | $30.3M | $27.9M | $23.0M | $22.1M | $17.0M | $13.8M | |
| Short-Term Investments | $0.00 | $0.00 | $8.9M | $0.00 | $12.3M | $13.3M | $15.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $10.2M | $7.4M | $28.0M | $22.6M | $78.4M | $45.5M | $29.3M | $24.0M | $22.7M | $17.4M | $14.3M | |
| Total Assets | $25.5M | $17.8M | $36.9M | $32.3M | $78.5M | $128.6M | $79.1M | $73.3M | $72.0M | $66.7M | $50.1M | |
| Total Current Liabilities | $2.1M | $5.2M | $13.7M | $10.5M | $2.0M | $3.3M | $3.4M | $1.7M | $1.9M | $2.1M | $1.3M | |
| Long-Term Debt | $1.4M | $1.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $3.8M | $11.4M | $25.9M | $13.9M | $8.5M | $20.4M | $11.2M | $11.6M | $5.4M | $2.8M | $1.9M | |
| Stockholders' Equity | $21.7M | $6.4M | $11.0M | $18.4M | $69.9M | $108.3M | $68.0M | $61.7M | $66.6M | $63.9M | $48.2M | |
| Retained Earnings | -$50.9M | -$56.0M | -$100.8M | -$178.6M | -$183.4M | -$155.8M | -$198.3M | -$211.1M | -$220.7M | -$228.5M | -$244.3M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.9M | -$9.7M | -$24.8M | -$32.4M | -$18.0M | -$17.2M | -$15.9M | -$12.3M | -$14.9M | -$8.9M | -$10.3M | |
| Capital Expenditure | -$2.6M | -$352.3K | -$534.0K | -$450.9K | -$86.7K | $0.00 | -$17.0K | -$22.0K | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$9.5M | -$10.0M | -$25.3M | -$32.9M | -$18.1M | -$17.2M | -$15.9M | -$12.4M | -$14.9M | -$8.9M | -$10.3M | |
| Investing Cash Flow | $6.9M | -$318.3K | -$9.4M | $11.5M | -$12.4M | -$3.5M | $13.2M | $104.0K | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $7.0M | $8.8M | $45.7M | $18.6M | $74.7M | $0.00 | $304.0K | $7.4M | $14.0M | $3.7M | $4.0M | |
| Issuance of Stock | $7.0M | $8.5M | $44.9M | $9.9M | $74.5M | $0.00 | $304.0K | $7.5M | $15.0M | $3.7M | $5.6M | |
| Repurchase of Stock | $0.00 | -$31.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | -$2.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $719.4K | $777.0K | $2.8M | $1.5M | $1.3M | $1.8M | $913.0K | $730.0K | $798.0K | $395.0K | |
| Net Change in Cash | -$3.0M | -$1.2M | $10.4M | -$3.7M | $46.1M | -$20.6M | -$2.5M | -$4.9M | -$872.0K | -$5.2M | -$6.2M |
Dilution Tracker
Shares outstanding grew 568.1% over 5 years — significant dilution
Shares Outstanding
16M
5-Year Share Growth
+568.1%
Stock Issuance (TTM)
$5.6M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.23 | 0.36 | 1.13 | 1.76 | 2.47 | 6.14 | 7.44 | 9.53 | 12.09 | 16.51 | 17.27 | |
| Change vs Prior % | — | 57.6% | 210.5% | 55.8% | 40.2% | 148.5% | 21.1% | 28.2% | 26.8% | 36.6% | 4.6% | |
| Stock Issuance | $7.0M | $8.5M | $44.9M | $9.9M | $74.5M | $0.00 | $304.0K | $7.5M | $15.0M | $3.7M | $5.6M | |
| Stock Repurchase | $0.00 | -$31.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $719.4K | $777.0K | $2.8M | $1.5M | $1.3M | $1.8M | $913.0K | $730.0K | $798.0K | $395.0K |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | 61.2% | — | — | — | — | — | — | |
| Operating Margin % | — | — | — | — | -8377.1% | — | — | — | — | — | — | |
| Net Margin % | — | — | — | — | -10039.8% | — | — | — | — | — | — | |
| EBITDA Margin % | — | — | — | — | -5069.9% | — | — | — | — | — | — | |
| FCF Margin % | — | — | — | — | -5843.5% | — | — | — | — | — | — | |
| ROE % | -48.6% | -261.5% | -356.4% | -277.5% | -44.4% | -11.3% | -84.4% | -28.2% | -20.5% | -12.2% | -35.8% | |
| ROA % | -41.4% | -93.7% | -106.7% | -157.8% | -39.6% | -9.5% | -72.5% | -23.8% | -18.9% | -11.7% | -42.8% | |
| ROIC % | -44.6% | -121.1% | -139.9% | -221.2% | -33.8% | -14.6% | -76.0% | -21.3% | -25.4% | -14.1% | -48.8% | |
| R&D / Revenue % | — | — | — | — | 2129.1% | — | — | — | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -1.3% | -4.4% | -16.4% | 100.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | -7.1% | -44.9% | -125.6% | -41.9% | 46.9% | 24.8% | -262.2% | 75.3% | -36.2% | 53.4% | |
| Net Income | -126.5% | -57.7% | -136.4% | -29.5% | 39.1% | 60.5% | -367.8% | 69.6% | 21.9% | 42.8% | |
| EPS (Diluted) | -54.9% | -29.8% | 21.5% | 38.2% | 56.3% | 84.0% | -282.2% | 76.3% | 38.3% | 58.4% | |
| Operating Cash Flow | -43.1% | -39.7% | -155.7% | -30.9% | 44.6% | 4.2% | 7.7% | 22.5% | -20.8% | 40.5% | |
| Free Cash Flow | -85.7% | -5.6% | -152.0% | -29.9% | 45.1% | 4.7% | 7.6% | 22.4% | -20.6% | 40.5% | |
| R&D Expense | 28.7% | 68.9% | 142.1% | 8.7% | -79.4% | 5.5% | 94.2% | -52.9% | 113.1% | -82.2% | |
| SG&A Expense | -49.1% | 305.6% | 37.6% | 294.1% | -37.9% | 16.4% | -9.1% | -18.8% | 13.1% | -15.0% | |
| Total Assets | 21.1% | -30.2% | 107.5% | -12.4% | 142.9% | 63.9% | -38.5% | -7.4% | -1.8% | -7.4% | |
| Book Value / Share | 3.9% | -81.4% | -44.1% | 6.7% | 171.4% | -37.7% | -48.2% | -29.1% | -14.9% | -29.8% | |
| Debt | 0.0% | -11.3% | 9.0% | -84.7% | -48.0% | 173.1% | 64.4% | -100.0% | 0.0% | 0.0% | |
| Diluted Shares | 4.1% | 57.6% | 210.5% | 55.8% | 40.2% | 148.5% | 21.1% | 28.2% | 26.8% | 36.6% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.66
10Y Low / Med / High0.04 / 0.41 / 1.20
EV/EBITDAAt Loss
10Y Low / Med / High0.20 / 0.30 / 3.48
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.70
Tangible Book / Share
$0.72
Net Current Assets / Share
$0.77
Graham Net-Net
$0.69
Cash / Share
$0.80
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.09 | -0.07 | -0.09 | -0.15 | -0.30 | -1.49 | -0.39 | -1.64 | -2.02 | -9.85 | -1.47 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 30.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.04 | 0.22 | 0.41 | 0.41 | 0.13 | 0.17 | 0.33 | 0.46 | 0.41 | 1.20 | 0.66 | |
| EV/EBITDA | -0.29 | 0.26 | 0.30 | 0.26 | 3.48 | 0.60 | 0.20 | -0.37 | -0.23 | -5.37 | -0.64 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | -176.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
5.49
Safe
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $5.0M | $5.0M | $100.0M |
| Net Income | -$11.5M | -$7.7M | $26.4M |
| EPS | $-0.68 | $-0.47 | $1.60 |
| # Analysts (EPS) | 1 | 2 | 1 |